Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation (Q31042226)

9 September 2017

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation (English)

1 reference

9 September 2017

1 reference

1 reference

1 reference

7

Dan M Roden

1 reference

9 September 2017

4

George K Dresser

1 reference

9 September 2017

Inna Y Gong

1

1 reference

9 September 2017

Ute I Schwarz

2

1 reference

9 September 2017

Natalie Crown

3

1 reference

9 September 2017

Alejandro Lazo-Langner

5

1 reference

9 September 2017

GuangYong Zou

6

1 reference

9 September 2017

C Michael Stein

8

1 reference

9 September 2017

Marc Rodger

9

1 reference

9 September 2017

Philip S Wells

10

1 reference

9 September 2017

Richard B Kim

11

1 reference

9 September 2017

Rommel G Tirona

12

1 reference

9 September 2017

language of work or name

English

0 references

publication date

16 November 2011

1 reference

9 September 2017

1 reference

9 September 2017

6

1 reference

9 September 2017

e27808

1 reference

9 September 2017

11

1 reference

Creative Commons Attribution 4.0 International

9 September 2017

start time

16 November 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Warfarin dosing in patients with impaired kidney function

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Integration of genetic, clinical, and INR data to refine warfarin dosing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

A new equation to estimate glomerular filtration rate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Kidney function influences warfarin responsiveness and hemorrhagic complications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

CYP4F2 genetic variant alters required warfarin dose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Drug interactions with warfarin: what clinicians need to know

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Association of warfarin dose with genes involved in its action and metabolism

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Risk of major hemorrhage for outpatients treated with warfarin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Human P450 metabolism of warfarin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

The influence of age, liver size and enantiomer concentrations on warfarin requirements

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Comparison of four basic models of indirect pharmacodynamic responses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

The effect of dietary vitamin K on warfarin-induced anticoagulation.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

The association of vitamin K status with warfarin sensitivity at the onset of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Practical application of the 10-mg warfarin initiation nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0027808

Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3218053

R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat

25 November 2018

1 reference

12 December 2020

The incidence, magnitude, and time course of the amiodarone-warfarin interaction

1 reference

12 December 2020

New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

1 reference

12 December 2020

In Vivo and In Vitro Availability of Commercial Warfarin Tablets

1 reference

12 December 2020

Physiologic indirect response models characterize diverse types of pharmacodynamic effects

1 reference

12 December 2020

Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane

1 reference

12 December 2020

Kinetics of drug absorption, distribution, metabolism, and excretion

1 reference

12 December 2020

On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment

1 reference

12 December 2020

10.1371/JOURNAL.PONE.0027808

Identifiers

DOI

1 reference

9 September 2017

0 references

1 reference

9 September 2017

1 reference